Untitled

Abstract

Along with graft vasculopathy, malignancies comprise a major complication after heart transplant, with a rate of occurrence of 39.1% in 10 years. Skin cancers and posttransplant lymphoproliferative disorder are more common in adults, whereas lymphoma is more often shown in children. A major cause of malignancies after heart transplant is the use of increased doses of prophylactics needed during immunosuppressive therapy. Data, however, are scarce regarding the association between a particular immunosuppressive drug and a posttransplant malignancy. Compared with the general population, recipients have a higher incidence of malignancies after heart transplant, with an early onset and more aggressive disease. Solid tumors known to occur in heart transplant recipients include lung cancer, bladder and prostate carcinoma, adenocarcinoma of the oral cavity, stomach cancer, and bowel cancer, although the incidence is rare. The risk factors for development of a malignancy after heart transplant are the same as for the nontransplant population.

Advanced native-kidney carcinoma in a heart- and kidney-transplanted patient: a case report

“…When considering heart transplantation, tumors are the second long-term cause of mortality after graft vasculopathy [14][15][16]. Reported cumulative prevalence of malignancies in heart TRs ranges from 2.9% at 1 year to 31.9% at 10 years, being non-melanoma skin cancers and lymphoproliferative disorder the two most common entities [17,18]. Yet, controversial data are available claiming cancer rates comparable to that of general population [14].…”

COVID‐19 pandemic deteriorates aftercare attendance in heart transplant recipients independently of perceived impact on social life

“…5 Following transplantation, heart transplant (HTx) recipients remain at an increased risk of allograft rejection, 6 infectious diseases, 7 and are prone to malignancies due to immunosuppression. 8,9 Steady aftercare is crucial to prevent or treat those complications early. In our center, we experienced HTx-recipients skipping routine follow-up visits due to concerns about potential transmission of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) during outpatient visits, with one patient dying from an acute cardiocirculatory failure, presumably due to acute rejection.…”